Cargando…

Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation

PURPOSE: Patients with inoperable pancreatic adenocarcinoma have limited options, with traditional chemoradiation providing modest clinical benefit and an otherwise poor prognosis. Stereotactic body radiation therapy for pancreatic cancer is limited by proximity to organs-at-risk (OAR). However, ste...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassanzadeh, Comron, Rudra, Soumon, Bommireddy, Ani, Hawkins, William G., Wang-Gillam, Andrea, Fields, Ryan C., Cai, Bin, Park, Justin, Green, Olga, Roach, Michael, Henke, Lauren, Kim, Hyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897757/
https://www.ncbi.nlm.nih.gov/pubmed/33665480
http://dx.doi.org/10.1016/j.adro.2020.06.010
_version_ 1783653731699523584
author Hassanzadeh, Comron
Rudra, Soumon
Bommireddy, Ani
Hawkins, William G.
Wang-Gillam, Andrea
Fields, Ryan C.
Cai, Bin
Park, Justin
Green, Olga
Roach, Michael
Henke, Lauren
Kim, Hyun
author_facet Hassanzadeh, Comron
Rudra, Soumon
Bommireddy, Ani
Hawkins, William G.
Wang-Gillam, Andrea
Fields, Ryan C.
Cai, Bin
Park, Justin
Green, Olga
Roach, Michael
Henke, Lauren
Kim, Hyun
author_sort Hassanzadeh, Comron
collection PubMed
description PURPOSE: Patients with inoperable pancreatic adenocarcinoma have limited options, with traditional chemoradiation providing modest clinical benefit and an otherwise poor prognosis. Stereotactic body radiation therapy for pancreatic cancer is limited by proximity to organs-at-risk (OAR). However, stereotactic magnetic resonance-guided adaptive radiation therapy (SMART) has shown promise in delivering ablative doses safely. We sought to demonstrate the benefits of SMART using a 5-fraction approach with daily on-table adaptation. METHODS AND MATERIALS: Patients with locally advanced, nonmetastatic pancreatic adenocarcinoma were treated with 50 Gy in 5 fractions (biologically effective dose(10) 100 Gy) with a prescribed goal of 95% planning target volume coverage by 95% of prescription, prioritizing hard OAR constraints. Daily online adaptation was performed using magnetic resonance-guidance and on-table reoptimization. Patient outcomes, treatment factors, and daily adaptation were evaluated. RESULTS: Forty-four patients were treated with SMART at our institution from 2014 to 2019. Median follow-up from date of diagnosis was 16 months (range, 6.7-51.6). Late toxicity was limited to 2 (4.6%) grade 3 (gastrointestinal ulcers) and 3 (6.8%) grade 2 toxicities (duodenal perforation, antral ulcer, and gastric bleed). Tumor abutted OARs in 35 patients (79.5%) and tumor invaded OARs in 5 patients (11.1%). Reoptimization was performed for 93% of all fractions. Median overall survival was 15.7 months (95% confidence interval, 10.2-21.2), while 1-year and 2-year overall survival rates were 68.2% and 37.9%, respectively. One-year local control was 84.3%. CONCLUSIONS: This is the first reported experience using 50 Gy in 5 fractions for inoperable pancreatic cancer. SMART allows this ablative dose with promising outcomes while minimizing toxicity. Additional prospective trials evaluating efficacy and safety are warranted.
format Online
Article
Text
id pubmed-7897757
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-78977572021-03-03 Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation Hassanzadeh, Comron Rudra, Soumon Bommireddy, Ani Hawkins, William G. Wang-Gillam, Andrea Fields, Ryan C. Cai, Bin Park, Justin Green, Olga Roach, Michael Henke, Lauren Kim, Hyun Adv Radiat Oncol Clinical Investigation PURPOSE: Patients with inoperable pancreatic adenocarcinoma have limited options, with traditional chemoradiation providing modest clinical benefit and an otherwise poor prognosis. Stereotactic body radiation therapy for pancreatic cancer is limited by proximity to organs-at-risk (OAR). However, stereotactic magnetic resonance-guided adaptive radiation therapy (SMART) has shown promise in delivering ablative doses safely. We sought to demonstrate the benefits of SMART using a 5-fraction approach with daily on-table adaptation. METHODS AND MATERIALS: Patients with locally advanced, nonmetastatic pancreatic adenocarcinoma were treated with 50 Gy in 5 fractions (biologically effective dose(10) 100 Gy) with a prescribed goal of 95% planning target volume coverage by 95% of prescription, prioritizing hard OAR constraints. Daily online adaptation was performed using magnetic resonance-guidance and on-table reoptimization. Patient outcomes, treatment factors, and daily adaptation were evaluated. RESULTS: Forty-four patients were treated with SMART at our institution from 2014 to 2019. Median follow-up from date of diagnosis was 16 months (range, 6.7-51.6). Late toxicity was limited to 2 (4.6%) grade 3 (gastrointestinal ulcers) and 3 (6.8%) grade 2 toxicities (duodenal perforation, antral ulcer, and gastric bleed). Tumor abutted OARs in 35 patients (79.5%) and tumor invaded OARs in 5 patients (11.1%). Reoptimization was performed for 93% of all fractions. Median overall survival was 15.7 months (95% confidence interval, 10.2-21.2), while 1-year and 2-year overall survival rates were 68.2% and 37.9%, respectively. One-year local control was 84.3%. CONCLUSIONS: This is the first reported experience using 50 Gy in 5 fractions for inoperable pancreatic cancer. SMART allows this ablative dose with promising outcomes while minimizing toxicity. Additional prospective trials evaluating efficacy and safety are warranted. Elsevier 2020-06-25 /pmc/articles/PMC7897757/ /pubmed/33665480 http://dx.doi.org/10.1016/j.adro.2020.06.010 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Clinical Investigation
Hassanzadeh, Comron
Rudra, Soumon
Bommireddy, Ani
Hawkins, William G.
Wang-Gillam, Andrea
Fields, Ryan C.
Cai, Bin
Park, Justin
Green, Olga
Roach, Michael
Henke, Lauren
Kim, Hyun
Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation
title Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation
title_full Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation
title_fullStr Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation
title_full_unstemmed Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation
title_short Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation
title_sort ablative five-fraction stereotactic body radiation therapy for inoperable pancreatic cancer using online mr-guided adaptation
topic Clinical Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897757/
https://www.ncbi.nlm.nih.gov/pubmed/33665480
http://dx.doi.org/10.1016/j.adro.2020.06.010
work_keys_str_mv AT hassanzadehcomron ablativefivefractionstereotacticbodyradiationtherapyforinoperablepancreaticcancerusingonlinemrguidedadaptation
AT rudrasoumon ablativefivefractionstereotacticbodyradiationtherapyforinoperablepancreaticcancerusingonlinemrguidedadaptation
AT bommireddyani ablativefivefractionstereotacticbodyradiationtherapyforinoperablepancreaticcancerusingonlinemrguidedadaptation
AT hawkinswilliamg ablativefivefractionstereotacticbodyradiationtherapyforinoperablepancreaticcancerusingonlinemrguidedadaptation
AT wanggillamandrea ablativefivefractionstereotacticbodyradiationtherapyforinoperablepancreaticcancerusingonlinemrguidedadaptation
AT fieldsryanc ablativefivefractionstereotacticbodyradiationtherapyforinoperablepancreaticcancerusingonlinemrguidedadaptation
AT caibin ablativefivefractionstereotacticbodyradiationtherapyforinoperablepancreaticcancerusingonlinemrguidedadaptation
AT parkjustin ablativefivefractionstereotacticbodyradiationtherapyforinoperablepancreaticcancerusingonlinemrguidedadaptation
AT greenolga ablativefivefractionstereotacticbodyradiationtherapyforinoperablepancreaticcancerusingonlinemrguidedadaptation
AT roachmichael ablativefivefractionstereotacticbodyradiationtherapyforinoperablepancreaticcancerusingonlinemrguidedadaptation
AT henkelauren ablativefivefractionstereotacticbodyradiationtherapyforinoperablepancreaticcancerusingonlinemrguidedadaptation
AT kimhyun ablativefivefractionstereotacticbodyradiationtherapyforinoperablepancreaticcancerusingonlinemrguidedadaptation